Please login or register to print this page.

Clinical Articles, Lead Article

‘True’ costs of NOACs assessed

Health economic studies are now assessing the true costs of non-vitamin K antagonist oral anticoagulants (NOACs) compared to warfarin. One study presented at the congress by Dr Elizabeth A Magnuson (Saint Luke’s Mid-America Heart Institute, Kansas City, USA) showed that compared with warfarin, edoxaban 60 mg (30 mg dose-reduced) once daily significantly reduced the overall rate of cardiovascular complications and bleeding-related hospitalisations and associated hospitalisation costs. 1

The investigators looked at 14,024 patients in the ENGAGE AF-TIMI 48 study and compared hospitalization rates. Rates (per 100 patient-years) of cardiovascular-related admissions, including haemorrhagic and ischaemic stroke, were lower with edoxaban (60/30 mg) than warfarin (12.8 vs. 13.9; p<0.0001). Rates of total non-stroke bleeding-related admissions were also lower with edoxaban (60/30 mg)  (2.38 vs. 2.45; p<0.0001), due to fewer subdural/epidural haematomas (0.10 vs. 0.23; p<0.0001) and extracranial bleeding complications (1.08 vs. 1.14; p<0.0001). Overall, total cardiovascular bleeding hospitalisation costs were US$147/patient-year less with edoxaban (60/30 mg) compared to warfarin (p=0.0004).

This “may to some extent offset increased drug treatment costs associated with edoxaban versus warfarin,”  said Dr Magnuson.

Reference

1. Magnuson E at al. Hospitalization-related costs among patients with atrial fibrillation treated with the factor Xa inhibitor edoxaban vs warfarin: results from the ENGAGE AF-TIMI 48 trial. Abstract P4970. Eur Heart J 2016;37(Abstract supplement):1007.

Published on: October 19, 2016

Members Area

Log in or Register now.

 For healthcare professionals only
Learning sky

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.